Article

Synthesis of the Isodityrosine Moiety of Seongsanamide A–D and Its Derivatives

Yang Xie [1], Zhou Xu [2], Pei Hu [2], Xiao-Ting Tian [2], Yi-Hong Lu [2], Hao-Dong Jiang [2], Cheng-Gang Huang [2,*] and Zhi-Cai Shang [1,*]

1 Department of Chemistry, Zhejiang University, Hangzhou 310027, China; sunshine_xie@163.com
2 Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; xz_619@163.com (Z.X.); hupeishtcm@126.com (P.H.); zhghydxtxt@163.com (X.-T.T.); xiong1743771101@163.com (Y.-H.L.); 18838916947@163.com (H.-D.J.)
* Correspondence: cghuang3208@126.com (C.-G.H.); shangzc@zju.edu.cn (Z.-C.S.)

Abstract: The concise and highly convergent synthesis of the isodityrosine unit of seongsanamide A–D and its derivatives bearing a diaryl ether moiety is described. In this work, the synthetic strategy features palladium-catalyzed $C(sp^3)$–H functionalization and a Cu/ligand-catalyzed coupling reaction. We report a practical protocol for the palladium-catalyzed mono-arylation of β-methyl $C(sp^3)$–H of an alanine derivative bearing a 2-thiomethylaniline auxiliary. The reaction is compatible with a variety of functional groups, providing practical access to numerous β-aryl-α-amino acids; these acids can be converted into various tyrosine and dihydroxyphenylalanine (DOPA) derivatives. Then, a CuI/*N,N*-dimethylglycine-catalyzed arylation of the already synthesized DOPA derivatives with aryl iodides is described for the synthesis of isodityrosine derivatives.

Keywords: $C(sp^3)$–H functionalization; palladium; arylation; isodityrosine; diaryl ether

1. Introduction

In 2018, Choi and coworkers [1] reported the isolation of seongsanamide A–D from a bacterial culture broth of *Bacillus safensis* KCTC 12796BP, obtained from a marine sponge collected in water samples of Seongsan on Jeju Island. Seongsanamides are bicyclic depsipeptides with an isodityrosine residue and exhibit antiallergenic properties (Figure 1). Furthermore, isodityrosine is a tyrosine dimer containing oxidatively coupled aromatic nuclei, and the tyrosine units are linked through a diaryl ether moiety [2]. A large class of biological cyclopeptides containing this structural unit exists in nature, with a wide range of pharmaceutical activities, such as seongsanamidesA–D, K-13 [3], OF4949-III [3], rubiyunnanin D [4], and bouvardin [5].


Figure 1. Structures of the seongsanamides A–D and isodityrosine.

In addition, diaryl ether (DE) is a functional scaffold that exists widely in both natural products and new drugs approved for the market [6]. Moreover, DE is always considered

the fundamental fragment of a wide variety of medicinal and agrochemical agents as well as their bioisosteres (Figure 2). Over the years, medicinal chemists have exploited the use of privileged structures inspired by natural products in drug discovery. The introduction of functional groups, such as α-keto [7] amide and *gem*-dimethyl [8] moieties, into biologically active small molecules has emerged as an efficient way to obtain clinically useful drugs.


Figure 2. Representative drugs bearing diaryl ether and theirbioisosteres.

Due to their potential structural diversity, pharmaceutical value, and good drug-gability, isodityrosines and cyclopeptide derivatives have attracted increasing attention in the synthetic community. Numerous research laboratories have engaged in the total synthesis of these natural products or analogs, including Dötz benzannulation [9], $S_N Ar$ reactions [10], and the Ullman [11–16] and Evans–Chan–Lam [3,17,18] coupling reactions. However, the synthesis of isodityrosines and their derivatives usually begins with available natural amino acids, limiting the diversity of the synthesis of their derivatives and their applications in drug design.

To address these challenges, we aimed to establish a convenient and convergent synthetic route. In recent years, transition-metal-catalyzed C–H functionalization has provided general and practical access to various natural and unnatural aromatic amino acids [19–23]. Our retrosynthetic analysis of the isodityrosine moiety of seongsanamides is outlined in Scheme 1. We selected a strategy based on palladium-catalyzed C(sp³)–H functionalization and copper-catalyzed Ullmann coupling reactions. The iodityrosine moiety was prepared from key precursor **1** and 4-iodophenylalaninederivatives via a C–O coupling reaction. The DOPA derivative **1** was derived from intermediate **2** by removing hydroxyl protecting groups, Dakin oxidation of aldehyde, or Baeyer–Villiger oxidation of acetyl group. Compound **2** was prepared by removing the directing group of **3**, which resulted from the palladium-catalyzed monoarylation of β-methyl C(sp³)–H of an alanine derivative with aryl iodides using a directing group. The structural diversity of aryl iodides could facilitate the synthesis of more isodityrosine derivatives.


Scheme 1. Retrosynthetic analysis of the isodityrosine moiety.

2. Results

Our study began with the synthesis of *N*-phthaloylalanine derivatives **4a–c** to examine potential amide directing groups (phthaloyl = Phth). Several commercially available aniline-based auxiliary groups, including 8-aminoquinoline [24–26], 2-thiomethylaniline (ArS) [27], and *O*-methylhydroxylamine [28], were selected for the palladium-catalyzed arylation. Subsequently, the treatment of 2-methoxybenzaldehyde with *N*-iodosuccinimide(NIS) and FeCl$_3$ produced the corresponding aryl iodide**5a**,with a yield of 89%.

Initially, the selectivity for mono- versus diarylation needed to be controlled. We initiated our investigation with the selective methyl C(sp^3)–H monoarylation of alanine derivative with aryl iodide (**5a**) as the model system (Scheme 2). In 2012, Daugulis reported that the selective β-monoarylation of alanine derivatives occurred under solvent-free conditions in high yield using a 2-thiomethylaniline auxiliary [27]. In 2014, Bull reported that the 3-monoarylation of proline derivatives under solvent-free conditions with 8-aminoquinoline directing groups was also successful [26]. Previously, Shi reported that the use of coordinating solvents, such as dimethylamine (DMA) and dimethylpropyleneurea(DMPU), improved the selectivity in the arylation of alanine derivatives with aryl iodides [29].

Scheme 2. Palladium-catalyzed arylation of **4a–c** with **5a**.

Due to these studies, we selected solvent-free conditions using palladium (II) acetate (Pd(OAc)$_2$, 20 mol%), silver acetate (AgOAc, 1.5 equiv), and DMPU (5.0 equiv) as additives. In accordance with reported results, the arylation of **4b** bearing an 8-aminoquinoline auxiliary mainly produced diarylated product **3ab** when the reaction was conducted at 150 °C, and **4a** bearing a 2-thiomethylaniline auxiliary mainly produced monoarylated product **3a** (Table 1, entries 1 and 2). The optimization of this transformation continued with **4a**. We aimed to maximize the yield of **3a** and the selectivity of monoarylation. We found that lowering the reaction temperature to 100 °C improved both the yield and selectivity of the reaction (48% yield, mono/di 12:1; Table 1, entry 3). Further screening showed that running the reaction at 80 °C increased both mono-selectivity and yield (62% yield, Table 1, entry 4). However, no satisfactory result was obtained when the reaction was run at 60 °C (42% yield, Table 1, entry 5).

Table 1. Palladium-catalyzed arylation of **4a–c** with **5a**.

Entry	Substrate	Temp.	Time	Yield (%)	Ratio (mono/di) [g]
1 [a]	**4a**	150 °C	24 h	38 [e]	2.2:1 [h]
2 [a]	**4b**	150 °C	24 h	12 [e]	1:3.1 [h]
3 [b]	**4a**	100 °C	48 h	48 [e]	12:1
4 [b]	**4a**	80 °C	48 h	62 [e]	mono
5 [b]	**4a**	60 °C	60 h	42 [f]	mono
6 [c]	**4b**	80 °C	48 h	26 [f]	1:1.7
7 [d]	**4c**	80 °C	48 h	36 [e]	mono
8 [i]	**4a**	80 °C	48 h	65 [e]	–
9 [j]	**4a**	80 °C	48 h	51 [e]	–

[a] **4** (0.6 mmol) was used. [b] **4a** (1.5 mmol) was used. [c] **4b** (1.5 mmol) was used. [d] **4c** (4.0 mmol) was used. [e] Isolated yields. [f] Yields are based on ^{1}H-NMR analysis. [g] The ratio of the mono- to the diarylated product was determined via ^{1}HNMR spectroscopy of the crude reaction mixture. [h] The ratio of the mono- to the diarylated product was determined via isolated yield. [i] **4a** (4.4 mmol) was used. [j] **4a** (18.5 mmol) was used.

Additional optimization experiments showed that the more strongly coordinating 8-aminoquinoline auxiliary still provided a predominantly diarylated product at 80 °C (mono/di 1:1.7; Table 1, entry 6). Interestingly, the palladium-catalyzed C(sp^3)–H arylation of Weinreb amides **4c** bearing an *N*-methoxyamide auxiliary was also successful, with a 36% yield(Table 1, entry 7). Notably, the reaction was also successful on a larger scale, and the yields were similar to those obtained on a smaller scale (Table 1, entries 8 and 9).

With the optimized the reaction conditions for the β-monoarylation of alanine-derived amide **4a**, we next investigated the scope of alkyl iodides that were compatible in the reaction (Scheme 3). A wide range of aryl iodides with different electron-withdrawing functional groups, such as formyl (**3b**, 53%; **3c**, 51%), acetyl (**3e**, 54%; **3f**, 57%), bromo (**3n**, 60%), and methoxycarbonyl (**3j**, 71%) groups underwent efficient monoarylation to produce the corresponding substituted phenylalanines in moderate yields (see Supplementary Materials). Moreover, aryl iodide bearing a nitro (**3p**) substituent was less reactive and successful, affording a 36% yield. Additionally, aryl iodides bearing alkoxy (**3g**, 76%; **3h**, 60%; **3i**, 56%) substituents were compatible with this protocol to produce their desired products in moderate to good yields.


^a 2.0 equiv. of Ar-I was used

Scheme 3. Palladium-catalyzed monoarylation of **4a** with aryl iodides.

Importantly, 3,4-disubstituted aryl iodides bearing one alkoxy group and an electron-withdrawing functional group also reacted smoothly under the standard conditions to produce the β-monoarylation products in moderate yields (**3d**, 55%; **3k**, 57%; **3l**, 60%; **3m**, 57%). In general, aryl iodides carrying electron-donating groups are more reactive than aryl iodides bearing electron-withdrawing groups. Also proving to be compatible were 3,4-Disubstituted aryl iodides, albeit with reduced yields (**3r**, 33%; **3s**, 36%).

However, an unfavorable steric effect was also apparent in 2-substituted aryl iodides, and decreased reactivity was also evident; sterically hindered immediately adjacent to the iodide decreased reactivity. Notably, steric aryl iodides were also compatible with the reaction conditions, although they were less reactive (**3t**, 36%; **3u**, 46%; **3v**, 33%). Interestingly, the 4-tert-butoxycarbonylamino- and 4-iodo-aryl derivatives were also successful, providing handles for potential further functionalization (**3o**, 46%; **3q**, 40%).

Based on our access to a wide range of phenylalanine derivatives, we subsequently examined the removal of the directing group. The sequential transformation of formyl, acetyl, and alkoxy groups to hydroxyl groups provided various tyrosine and DOPA derivatives that could be used to produce more isodityrosine derivatives via the Ullmann coupling re-

action. The directing group of **3a** was easily removed by treatment with H_2SO_4 in methanol (MeOH) to produce the corresponding methyl ester **2a** with a 77% yield (Scheme 4). The treatment of aldehyde **2a** with *m*-CPBA produced the formate ester, which was immediately converted into the corresponding phenol **1** (74% yield for two steps).

Scheme 4. Synthesis of DOPA derivative **1**.

Subsequently, we focused on the second key step, the copper-catalyzed Ullmann coupling reaction of DOPA derivative **1** (Scheme 5, see Supplementary Materials). The development of useful methods via the Cu/ligand-catalyzed arylation of phenols for assembling diaryl ethers was accomplished [30–34]. Initially, we selected the coupling of phenylalanine-derived aryl iodides (1.5 equiv), with **1** as a model reaction to optimize the reaction conditions. The coupling reaction was tested in the presence of CuI (1.0 equiv) and Cs_2CO_3 (4.5 equiv) when the reaction was carried out in 1,4-dioxane (0.1 M) under N_2 at 90 °C for 20 h. We tested several ligands that are known to promote copper-catalyzed coupling reactions. Interestingly, we found that using commercially available *N,N*-dimethylglycine as a ligand produced the corresponding products. Moreover, several phenylalanine-derived aryl iodides with different protecting groups at the C-terminus were compatible with the reaction conditions (**6a**, 49%; **6b**, 50%; **6c**, 44%). Notably, in isodityrosine derivatives **6a–d**, all amino and carboxylate groups with different protections enabled the selective manipulation of the individual functionalities.

a 3.0 equiv. of Ar-I was used.

Scheme 5. Coupling of the aryl iodides with DOPA derivative **1**.

With the optimized reaction conditions, we next examined an extensive range of aryl iodides to produce a 3-aryloxyphenylalanine derivative bearing a diaryl ether moiety. A variety of functional groups of aryl iodides are known to tolerate this reaction condition, including alkoxyl, formyl, acetyl, nitro, carbonyl, iodo, and cyano groups. Both electron-rich and electron-deficient aryl iodides underwent this reaction to produce the corresponding diaryl ethers in good yields. A high yield was provided by 4-iodobenzaldehyde (**6e**, 88%), whereas 3-iodobenzaldehyde provided a 52% yield under standard conditions. Furthermore, aromatics with aldehyde and methoxyl groups were also compatible, with reduced yields (**6g**, 30%). Notably, the reaction of 1,4-diiodobenzene with phenol **1** produced the

coupling product **6j** in 64% yield, which was a 3-(4-iodoaryloxy)-phenylalanine derivative and provided a handle for potential further functionalization.

In conclusion, we have developed a convenient and highly convergent synthesis of the isodityrosine unit of seongsanamide A–D and its derivatives bearing a diaryl ether moiety. The synthetic sequence is based on a palladium-catalyzed C(sp^3)–H functionalization and a Cu/ligand-catalyzed coupling reaction. Initially, we developed a Pd-catalyzed mono-arylation of β-methyl C(sp^3)–H of an alanine derivative using the 2-thiomethylaniline directing group. A wide range of aryl iodides could be applied in this protocol to provide various aromatic α-amino acid compounds; these compounds could be used for the synthesis of various tyrosine and DOPA derivatives. Subsequently, the CuI/*N,N*-dimethylglycine-catalyzed coupling of DOPA derivatives with aryl iodides was accomplished to prepare diaryl ethers and the synthesis of isodityrosine derivatives. Our convergent synthetic method facilitates a concise way for the efficient preparation of various DE-based analogs for drug development efforts. The specific introduction of DE-based units into biologically active small molecules and a study of the impact on the physicochemical properties and potential biological activities are currently being performed.

3. Materials and Methods

3.1. General Experimental Methods

Chemicals were acquired from commercial sources and used as received. Nuclear magnetic resonance (NMR) spectra were recorded on Bruker Ascend-400 and Bruker Ascend-500 spectrometers at the following spectrometer frequencies. Multiplicities are assigned as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), and app (apparent).The exact mass was obtained using a time-of-flight (TOF) detector on Agilent 6530-Q-TOF. Thin layer chromatography (TLC) was carried out with 0.2 mm thick silica gel plates. Visualization was accomplished by using UV light. Column chromatography was performed on silica gel (200–300 mesh).

3.2. Synthesis of the Phenylalanine Derivatives3a–v

A Schlenk tube was charged with **1** (1.5 mmol), aryl iodide (1.5 equiv., or 2.0 equiv. used for synthesis of **3o**), Pd(OAc)$_2$ (0.2 equiv.), AgOAc (2.0 equiv.), and DMPU (5.0 equiv.), evacuated, and backfilled with N$_2$. The reaction mixture was stirred at 80 °C for 48 h. The suspension was filtered, and the filtrate was concentrated, followed by column chromatography on silica gel (eluting with 1:5 to 1:2 ethyl acetate/petroleum ether) to provide the desired product.

(S)-N-(3-(4-Methoxy-3-formylphenyl)-2-phthalimidopropionyl)-2-methylthioaniline (**3a**). **3a** was obtained as a solid. ^{1}H NMR (400 MHz, CDCl$_3$) δ 10.30 (s, 1H), 8.94 (s, 1H), 8.31 (d, *J* = 8.1 Hz, 1H), 7.82 (dt, *J* = 7.1, 3.5 Hz, 2H), 7.79–7.67 (m, 2H), 7.64 (d, *J* = 2.2 Hz, 1H), 7.52–7.38 (m, 2H), 7.29 (dd, *J* = 13.5, 6.0 Hz, 1H), 7.06 (td, *J* = 7.6, 1.0 Hz, 1H), 6.86 (d, *J* = 8.6 Hz, 1H), 5.24 (dd, *J* = 10.6, 5.9 Hz, 1H), 3.84 (s, 3H), 3.68 (qd, *J* = 14.3, 8.3 Hz, 2H), 2.20 (s, 3H); ^{13}C NMR (101 MHz, CDCl$_3$) δ 189.45, 167.81, 166.20, 160.89, 137.97, 136.49, 134.63, 133.53, 131.43, 129.33, 129.13, 129.08, 125.64, 124.97, 124.82, 123.82, 120.70, 112.27, 56.30, 55.79, 33.40, 19.22; HRMS(ESI): *m/z* [M + H]$^+$calcd. for C$_{26}$H$_{23}$N$_2$O$_5$S$^+$: 475.1322, found: 475.1448.

(S)-N-(3-(3-Formylphenyl)-2-phthalimidopropionyl)-2-methylthioaniline (**3b**). **3b** was obtained as an oil. ^{1}H NMR (500 MHz, CDCl$_3$) δ 9.88 (s, 1H), 8.95 (s, 1H), 8.33 (d, *J* = 8.2 Hz, 1H), 7.81 (dt, *J* = 7.4, 3.7 Hz, 2H), 7.76–7.71 (m, 3H), 7.68 (d, *J* = 7.6 Hz, 1H), 7.52 (d, *J* = 7.6 Hz, 1H), 7.45 (t, *J* = 8.5 Hz, 1H), 7.39 (t, *J* = 7.6 Hz, 1H), 7.31 (t, *J* = 7.8 Hz, 1H), 7.07 (t, *J* = 7.6 Hz, 1H), 5.33 (dd, *J* = 10.9, 5.7 Hz, 1H), 3.80 (ddd, *J* = 25.2, 14.3, 8.4 Hz, 2H), 2.18 (s, 3H); ^{13}C NMR (126 MHz, CDCl$_3$) δ 192.11, 167.76, 166.03, 138.13, 137.90, 136.85, 135.14, 134.73, 133.56, 131.33, 130.59, 129.57, 129.39, 128.34, 125.59, 125.04, 123.83, 120.66, 56.01, 34.14, 19.22; HRMS(ESI): *m/z* [M + H]$^+$calcd. for C$_{25}$H$_{21}$N$_2$O$_4$S$^+$: 445.1217, found: 445.1223.

(S)-N-(3-(4-Formylphenyl)-2-phthalimidopropionyl)-2-methylthioaniline (**3c**). **3c** was obtained as an oil. ^{1}H NMR (500 MHz, CDCl$_3$) δ 9.91 (d, *J* = 11.3 Hz, 1H), 8.94 (s, 1H), 8.32 (d,

J = 8.2 Hz, 1H), 7.81 (dt, *J* = 7.5, 3.8 Hz, 2H), 7.78–7.70 (m, 4H), 7.44 (d, *J* = 7.7 Hz, 1H), 7.39 (d, *J* = 7.9 Hz, 2H), 7.31 (t, *J* = 7.8 Hz, 1H), 7.07 (t, *J* = 7.6 Hz, 1H), 5.34 (dd, *J* = 10.7, 6.0 Hz, 1H), 3.87–3.72 (m, 2H), 2.17 (s, 3H); ^{13}C NMR (126 MHz, CDCl$_3$) δ 191.94, 167.71, 165.95, 144.18, 137.87, 135.37, 134.77, 133.57, 131.28, 130.25, 129.78, 129.41, 125.57, 125.07, 123.85, 120.63, 55.76, 34.56, 19.21; HRMS(ESI): *m/z* [M + H]$^+$calcd. for C$_{25}$H$_{21}$N$_2$O$_4$S$^+$: 445.1217, found: 445.1221.

(S)-N-(3-(4-(Benzyloxy)-3-formylphenyl)-2-phthalimidopropionyl)-2-methylthioaniline(**3d**). **3d** was obtained as a solid. ^{1}H NMR (500 MHz, CDCl$_3$) δ 10.40 (s, 1H), 8.94 (s, 1H), 8.32 (d, *J* = 8.2 Hz, 1H), 7.82 (dt, *J* = 7.3, 3.7 Hz, 2H), 7.76–7.70 (m, 2H), 7.67 (d, *J* = 2.1 Hz, 1H), 7.47–7.41 (m, 2H), 7.38 (d, *J* = 4.3 Hz, 4H), 7.36–7.32 (m, 1H), 7.30 (t, *J* = 7.6 Hz, 1H), 7.06 (t, *J* = 7.5 Hz, 1H), 6.93 (d, *J* = 8.6 Hz, 1H), 5.24 (dd, *J* = 10.7, 5.7 Hz, 1H), 5.10 (s, 2H), 3.68 (ddd, *J* = 25.1, 14.4, 8.3 Hz, 2H), 2.20 (s, 3H); ^{13}C NMR (126 MHz, CDCl$_3$) δ 189.36, 167.80, 166.18, 160.11, 137.96, 136.45, 136.03, 134.63, 133.55, 131.43, 129.52, 129.35, 128.91, 128.83, 128.41, 127.42, 125.61, 125.16, 124.97, 123.83, 120.69, 70.62, 56.27, 33.43, 19.23; HRMS(ESI): *m/z* [M + H]$^+$calcd. for C$_{32}$H$_{27}$N$_2$O$_5$S$^+$: 551.1635, found: 551.1674.

(S)-N-(3-((4-Acetylphenyl)-2-phthalimidopropionyl)-2-methylthioaniline (**3e**). **3e** was obtained as an oil. ^{1}H NMR (500 MHz, CDCl$_3$) δ 8.95 (s, 1H), 8.33 (d, *J* = 8.1 Hz, 1H), 7.81 (dt, *J* = 9.7, 4.8 Hz, 3H), 7.79 (s, 1H), 7.73 (dd, *J* = 5.3, 3.1 Hz, 2H), 7.44 (d, *J* = 7.6 Hz, 1H), 7.31 (t, *J* = 8.4 Hz, 3H), 7.07 (t, *J* = 7.5 Hz, 1H), 5.70–4.91 (m, 1H), 4.21–3.39 (m, 2H), 2.52 (s, 3H), 2.18 (s, 3H); ^{13}C NMR (126 MHz, CDCl$_3$) δ 197.86, 167.76, 166.08, 142.55, 137.93, 136.05, 134.73, 133.60, 131.34, 129.42, 129.31, 128.91, 125.56, 125.04, 123.85, 120.64, 55.88, 34.36, 26.70, 19.24; HRMS(ESI): *m/z* [M + H]$^+$calcd. for C$_{26}$H$_{23}$N$_2$O$_4$S$^+$: 459.1373, found: 459.1376.

(S)-N-(3-(3-Acetylphenyl)-2-phthalimidopropionyl)-2-methylthioaniline (**3f**). **3f** was obtained as an oil. ^{1}H NMR (500 MHz, CDCl$_3$) δ 8.96 (s, 1H), 8.33 (d, *J* = 8.2 Hz, 1H), 7.84–7.79 (m, 2H), 7.78 (s, 1H), 7.76–7.70 (m, 3H), 7.44 (d, *J* = 7.7 Hz, 2H), 7.35–7.28 (m, 2H), 7.07 (td, *J* = 7.6, 1.0 Hz, 1H), 5.32 (dd, *J* = 10.9, 5.7 Hz, 1H), 3.78 (ddd, *J* = 25.2, 14.3, 8.4 Hz, 2H), 2.47 (s, 3H), 2.19 (s, 3H); ^{13}C NMR (126 MHz, CDCl$_3$) δ 197.92, 167.78, 166.15, 137.92, 137.54, 137.43, 134.70, 133.79, 133.52, 131.37, 129.36, 129.16, 129.03, 127.08, 125.63, 125.02, 123.79, 120.70, 56.13, 34.25, 26.71, 19.21; HRMS(ESI): *m/z* [M + H]$^+$calcd. for C$_{26}$H$_{23}$N$_2$O$_4$S$^+$: 459.1373, found: 459.1378.

(S)-N-(3-(3-(Benzyloxy)phenyl)-2-phthalimidopropionyl)-2-methylthioaniline (**3g**). **3g** was obtained as an oil. ^{1}H NMR (400 MHz, CDCl$_3$) δ 8.96 (s, 1H), 8.34 (d, *J* = 8.1 Hz, 1H), 7.86–7.79 (m, 2H), 7.75–7.68 (m, 2H), 7.47–7.40 (m, 1H), 7.37–7.33 (m, 4H), 7.33–7.27 (m, 2H), 7.13 (dd, *J* = 14.3, 6.4 Hz, 1H), 7.07 (td, *J* = 7.6, 1.2 Hz, 1H), 6.90–6.80 (m, 2H), 6.76 (dd, *J* = 8.2, 2.1 Hz, 1H), 5.33 (dd, *J* = 10.7, 5.9 Hz, 1H), 4.91 (q, *J* = 11.6 Hz, 2H), 3.70 (qd, *J* = 14.2, 8.3 Hz, 2H), 2.20 (s, 3H); ^{13}C NMR (126 MHz, CDCl$_3$) δ 167.86, 166.46, 159.06, 138.31, 138.01, 136.92, 134.52, 133.51, 131.51, 129.87, 129.31, 128.63, 128.03, 127.54, 125.59, 124.91, 123.72, 121.59, 120.68, 115.25, 113.85, 69.93, 56.31, 34.49, 19.19; HRMS(ESI): *m/z* [M + H]$^+$calcd. for C$_{31}$H$_{27}$N$_2$O$_4$S$^+$: 523.1686, found: 523.1734.

(S)-N-(3-(4-(Benzyloxy)phenyl)-2-phthalimidopropionyl)-2-methylthioaniline (**3h**). **3h** was obtained as an oil. ^{1}H NMR (500 MHz, CDCl$_3$) δ 8.96 (s, 1H), 8.34 (d, *J* = 8.2 Hz, 1H), 7.86–7.79 (m, 2H), 7.75–7.69 (m, 2H), 7.45 (d, *J* = 7.6 Hz, 1H), 7.39–7.32 (m, 4H), 7.30 (dd, *J* = 10.4, 4.8 Hz, 2H), 7.14 (d, *J* = 8.5 Hz, 2H), 7.06 (t, *J* = 7.6 Hz, 1H), 6.81 (d, *J* = 8.6 Hz, 2H), 5.27 (dd, *J* = 10.6, 6.1 Hz, 1H), 4.96 (s, 2H), 3.74–3.60 (m, 2H), 2.20 (s, 3H); ^{13}C NMR (126 MHz, CDCl$_3$) δ 167.92, 166.58, 157.84, 138.08, 137.00, 134.50, 133.55, 131.53, 130.08, 129.33, 128.93, 128.66, 128.06, 127.58, 125.58, 124.89, 123.72, 120.71, 115.19, 70.04, 56.56, 33.67, 19.21; HRMS(ESI): *m/z* [M + H]$^+$ calcd. for C$_{31}$H$_{27}$N$_2$O$_4$S$^+$: 523.1686, found: 523.1700.

(S)-N-(3-(3,4-Dimethoxyphenyl)-2-phthalimidopropionyl)-2-methylthioaniline (**3i**). **3i** was obtained as a solid. ^{1}H NMR (500 MHz, CDCl$_3$) δ 8.98 (s, 1H), 8.33 (d, *J* = 8.2 Hz, 1H), 7.81 (dt, *J* = 7.5, 3.8 Hz, 2H), 7.76–7.69 (m, 2H), 7.44 (d, *J* = 7.7 Hz, 1H), 7.30 (t, *J* = 7.8 Hz, 1H), 7.06 (t, *J* = 7.6 Hz, 1H), 6.76 (d, *J* = 8.1 Hz, 1H), 6.69 (d, *J* = 7.9 Hz, 2H), 5.29 (dd, *J* = 10.9, 6.0 Hz, 1H), 3.77 (s, 3H), 3.70 (s, 3H), 3.69–3.60 (m, 2H), 2.21 (s, 3H); ^{13}C NMR (126 MHz, CDCl$_3$) δ 167.93, 166.59, 148.94, 147.94, 138.03, 134.57, 133.48, 131.51, 129.31, 129.03, 125.64,

124.93, 123.69, 121.20, 120.73, 111.84, 111.38, 56.53, 55.87, 55.80, 34.03, 19.16; HRMS(ESI): m/z [M + H]$^+$calcd. for $C_{26}H_{25}N_2O_5S^+$: 477.1479, found: 477.1492.

(S)-N-(3-(3-(Methoxycarbonyl)phenyl)-2-phthalimidopropionyl)-2-methylthioaniline (**3j**). **3j** was obtained as an oil. ^{1}H NMR (500 MHz, CDCl$_3$) δ 8.95 (s, 1H), 8.33 (d, *J* = 8.2 Hz, 1H), 7.89 (s, 1H), 7.82 (dt, *J* = 9.7, 4.9 Hz, 3H), 7.77–7.70 (m, 2H), 7.43 (t, *J* = 8.0 Hz, 2H), 7.30 (dt, *J* = 15.8, 7.9 Hz, 2H), 7.06 (t, *J* = 7.6 Hz, 1H), 5.31 (dd, *J* = 10.8, 5.6 Hz, 1H), 3.83 (s, 3H), 3.76 (ddd, *J* = 25.1, 14.3, 8.4 Hz, 2H), 2.19 (s, 3H); ^{13}C NMR (126 MHz, CDCl$_3$) δ 167.78, 166.83, 166.17, 137.97, 137.25, 134.60, 133.58, 131.42, 130.68, 130.18, 129.37, 128.93, 128.47, 125.58, 124.98, 123.79, 120.68, 56.19, 52.22, 34.19, 19.22; HRMS(ESI): m/z [M + H]$^+$calcd. for $C_{26}H_{21}N_2O_5S^+$: 475.1322, found: 475.1326.

(S)-N-(3-(4-(Benzyloxy)-3-(methoxycarbonyl)phenyl)-2-phthalimidopropionyl)-2-methylthioaniline (**3k**). **3k** was obtained as an oil. ^{1}H NMR (500 MHz, CDCl$_3$) δ 8.94 (s, 1H), 8.33 (d, *J* = 8.2 Hz, 1H), 7.85–7.79 (m, 2H), 7.76–7.70 (m, 2H), 7.65 (d, *J* = 2.3 Hz, 1H), 7.47–7.40 (m, 3H), 7.35 (dd, *J* = 10.3, 4.8 Hz, 2H), 7.33–7.27 (m, 3H), 7.06 (td, *J* = 7.6, 1.3 Hz, 1H), 6.88 (d, *J* = 8.6 Hz, 1H), 5.26 (dd, *J* = 10.6, 6.0 Hz, 1H), 5.09 (s, 2H), 3.79 (s, 3H), 3.67 (qd, *J* = 14.4, 8.3 Hz, 2H), 2.20 (s, 3H); ^{13}C NMR (126 MHz, CDCl$_3$) δ 167.85, 166.30, 166.24, 157.32, 138.01, 136.73, 134.58, 133.97, 133.56, 132.37, 131.49, 129.35, 128.84, 128.63, 127.88, 126.89, 125.61, 124.95, 123.80, 120.78, 120.71, 114.41, 70.71, 56.28, 52.06, 33.41, 19.21; HRMS(ESI): m/z [M + H]$^+$calcd. for $C_{33}H_{29}N_2O_6S^+$: 581.1741, found: 581.1753.

(S)-N-(3-(3-(Benzyloxy)-4-(methoxycarbonyl)phenyl)-2-phthalimidopropionyl)-2-methylthioaniline (**3l**). **3l** was obtained as an oil. ^{1}H NMR (500 MHz, CDCl$_3$) δ 8.95 (s, 1H), 8.33 (d, *J* = 8.1 Hz, 1H), 7.87–7.80 (m, 2H), 7.73 (td, *J* = 5.2, 2.1 Hz, 2H), 7.70 (t, *J* = 5.5 Hz, 1H), 7.45 (d, *J* = 7.5 Hz, 3H), 7.37 (dd, *J* = 10.3, 4.7 Hz, 2H), 7.34–7.27 (m, 2H), 7.07 (td, *J* = 7.6, 1.3 Hz, 1H), 6.90 (s, 1H), 6.88 (d, *J* = 7.9 Hz, 1H), 5.34 (dd, *J* = 9.5, 7.3 Hz, 1H), 5.02 (dd, *J* = 41.7, 11.9 Hz, 2H), 3.83 (s, 3H), 3.74 (dd, *J* = 12.0, 4.7 Hz, 2H), 2.19 (s, 3H); ^{13}C NMR (126 MHz, CDCl$_3$) δ 167.80, 166.51, 166.13, 158.58, 143.11, 137.92, 136.65, 134.75, 133.55, 132.50, 131.39, 129.39, 128.64, 127.90, 126.92, 125.62, 125.05, 123.86, 121.26, 120.67, 119.34, 114.41, 70.69, 55.75, 52.05, 34.52, 19.20; HRMS(ESI): m/z [M + H]$^+$calcd. for $C_{33}H_{29}N_2O_6S^+$: 581.1741, found: 581.1752.

(S)-N-(3-(3-Cyano-4-methoxyphenyl)-2-phthalimidopropionyl)-2-methylthioaniline (**3m**). **3m** was obtained as a solid. ^{1}H NMR (500 MHz, CDCl$_3$) δ 8.91 (s, 1H), 8.30 (d, *J* = 8.2 Hz, 1H), 7.84 (dt, *J* = 7.4, 3.7 Hz, 2H), 7.79–7.73 (m, 2H), 7.43 (d, *J* = 8.4 Hz, 2H), 7.37 (d, *J* = 1.8 Hz, 1H), 7.30 (t, *J* = 7.8 Hz, 1H), 7.06 (t, *J* = 7.6 Hz, 1H), 6.84 (d, *J* = 8.7 Hz, 1H), 5.22 (dd, *J* = 10.8, 5.7 Hz, 1H), 3.84 (s, 3H), 3.66 (ddd, *J* = 25.3, 14.4, 8.3 Hz, 2H), 2.18 (s, 3H); ^{13}C NMR (126 MHz, CDCl$_3$) δ 167.76, 165.92, 160.36, 137.79, 135.05, 134.83, 134.06, 133.47, 131.26, 129.48, 129.33, 125.63, 125.07, 123.91, 120.65, 116.21, 111.81, 101.95, 56.13, 55.96, 33.15, 19.17; HRMS(ESI): m/z [M + H]$^+$calcd. for $C_{26}H_{22}N_3O_4S^+$: 472.1326, found: 472.1341.

(S)-N-(3-(4-Bromophenyl)-2-phthalimidopropionyl)-2-methylthioaniline (**3n**). **3n** was obtained as an oil. ^{1}H NMR (500 MHz, CDCl$_3$) δ 8.93 (s, 1H), 8.32 (d, *J* = 8.2 Hz, 1H), 7.83 (dt, *J* = 7.2, 3.6 Hz, 2H), 7.78–7.70 (m, 2H), 7.44 (d, *J* = 7.6 Hz, 1H), 7.32 (d, *J* = 8.3 Hz, 2H), 7.30 (d, *J* = 7.6 Hz, 1H), 7.10 (d, *J* = 8.3 Hz, 2H), 7.07 (t, *J* = 7.6 Hz, 1H), 5.27 (dd, *J* = 10.3, 6.4 Hz, 1H), 3.73–3.64 (m, 2H), 2.19 (s, 3H); ^{13}C NMR (126 MHz, CDCl$_3$) δ 167.82, 166.19, 137.95, 135.82, 134.70, 133.59, 131.95, 131.39, 130.77, 129.40, 125.55, 125.01, 123.85, 121.09, 120.65, 56.03, 33.86, 19.24; HRMS(ESI): m/z [M + H]$^+$calcd. for $C_{24}H_{20}BrN_2O_3S^+$: 495.0373, found: 495.0375.

(S)-N-(3-(4-Iodophenyl)-2-phthalimidopropionyl)-2-methylthioaniline (**3o**). **3o** was obtained as an oil. ^{1}H NMR (400 MHz, CDCl$_3$) δ 8.92 (s, 1H), 8.31 (d, *J* = 8.2 Hz, 1H), 7.82 (dt, *J* = 7.1, 3.6 Hz, 2H), 7.77–7.71 (m, 2H), 7.52 (d, *J* = 8.2 Hz, 2H), 7.44 (d, *J* = 7.7 Hz, 1H), 7.30 (t, *J* = 7.8 Hz, 1H), 7.06 (t, *J* = 7.6 Hz, 1H), 6.98 (d, *J* = 8.2 Hz, 2H), 5.32–5.23 (m, 1H), 3.75–3.59 (m, 2H), 2.18 (s, 3H); ^{13}C NMR (126 MHz, CDCl$_3$) δ 167.82, 166.18, 137.88, 136.47, 134.68, 133.54, 131.37, 131.03, 129.37, 125.53, 124.99, 123.84, 120.64, 92.62, 55.97, 33.95, 19.22; HRMS(ESI): m/z [M + H]$^+$calcd. for $C_{24}H_{20}IN_2O_3S^+$: 543.0234, found: 543.0233.

(S)-N-(3-(3-Nitrophenyl)-2-phthalimidopropionyl)-2-methylthioaniline (**3p**). **3p** was obtained as a solid. ^{1}H NMR (400 MHz, CDCl$_3$) δ 8.93 (s, 1H), 8.32 (d, *J* = 8.2 Hz, 1H), 8.08 (s, 1H), 8.03 (d, *J* = 8.2 Hz, 1H), 7.83 (dt, *J* = 7.0, 3.5 Hz, 2H), 7.79–7.71 (m, 2H), 7.60 (d, *J* = 7.7 Hz,

1H), 7.42 (dd, *J* = 16.3, 8.1 Hz, 2H), 7.31 (t, *J* = 7.8 Hz, 1H), 7.08 (td, *J* = 7.6, 1.1 Hz, 1H), 5.32 (dd, *J* = 10.8, 5.6 Hz, 1H), 3.83 (ddd, *J* = 25.2, 14.4, 8.2 Hz, 2H), 2.18 (s, 3H); ^{13}C NMR (126 MHz, CDCl$_3$) δ 167.70, 165.71, 148.45, 139.13, 137.79, 135.30, 134.88, 133.57, 131.24, 129.82, 129.43, 125.59, 125.13, 124.07, 123.95, 122.36, 120.64, 55.74, 34.07, 19.23; HRMS(ESI): *m/z* [M + H]$^+$calcd. for C$_{24}$H$_{20}$N$_3$O$_5$S$^+$: 462.1118, found: 462.1161.

(S)-N-(3-(4-tert-Butoxycarbonylaminophenyl)-2-phthalimidopropionyl)-2-methylthioaniline (**3q**). **3q** was obtained as a solid. ^{1}H NMR (400 MHz, CDCl$_3$) δ 8.96 (s, 1H), 8.33 (d, *J* = 8.2 Hz, 1H), 7.81 (dt, *J* = 7.1, 3.6 Hz, 2H), 7.75–7.68 (m, 2H), 7.44 (d, *J* = 7.7 Hz, 1H), 7.30 (t, *J* = 7.8 Hz, 1H), 7.16 (dd, *J* = 25.0, 8.4 Hz, 4H), 7.06 (td, *J* = 7.7, 1.2 Hz, 1H), 6.37 (s, 1H), 5.27 (t, *J* = 8.4 Hz, 1H), 3.65 (t, *J* = 11.5 Hz, 2H), 2.20 (s, 3H), 1.47 (s, 9H); ^{13}C NMR (126 MHz, CDCl$_3$) δ 167.90, 166.53, 152.72, 138.07, 137.33, 134.53, 133.57, 131.50, 131.11, 129.58, 129.35, 125.58, 124.90, 123.76, 120.70, 118.69, 80.55, 56.45, 33.76, 28.43, 19.22; HRMS(ESI): *m/z* [M + H]$^+$calcd. for C$_{29}$H$_{30}$N$_3$O$_5$S$^+$: 532.1901, found: 532.1905.

(S)-N-(3-(4-Bromo-3-formylphenyl)-2-phthalimidopropionyl)-2-methylthioaniline (**3r**). **3r** was obtained as an oil. ^{1}H NMR (400 MHz, CDCl$_3$) δ 10.22 (s, 1H), 8.91 (s, 1H), 8.31 (t, *J* = 8.1 Hz, 1H), 7.87–7.81 (m, 2H), 7.78–7.72 (m, 3H), 7.50 (d, *J* = 8.2 Hz, 1H), 7.43 (d, *J* = 7.8 Hz, 1H), 7.35 (dd, *J* = 8.2, 2.3 Hz, 1H), 7.30 (t, *J* = 7.8 Hz, 1H), 7.07 (td, *J* = 7.6, 1.2 Hz, 1H), 5.27 (dd, *J* = 10.6, 5.8 Hz, 1H), 3.73 (qd, *J* = 14.1, 8.3 Hz, 2H), 2.18 (s, 3H); ^{13}C NMR (126 MHz, CDCl$_3$) δ 191.51, 167.71, 165.80, 137.79, 137.40, 136.01, 134.80, 134.37, 133.58, 133.54, 131.28, 130.39, 129.38, 125.68, 125.59, 125.08, 123.94, 120.65, 55.69, 33.66, 19.23; HRMS(ESI): *m/z* [M + Na]$^+$calcd. for C$_{25}$H$_{19}$BrN$_2$O$_4$SNa$^+$: 545.0141, found: 545.0183.

(S)-N-(3-(3-Bromo-4-formylphenyl)-2-phthalimidopropionyl)-2-methylthioaniline (**3s**). **3s** was obtained as an oil. ^{1}H NMR (400 MHz, CDCl$_3$) δ 10.22 (s, 1H), 8.91 (s, 1H), 8.30 (d, *J* = 8.1 Hz, 1H), 7.84 (dt, *J* = 7.0, 3.5 Hz, 2H), 7.76 (dt, *J* = 7.8, 3.9 Hz, 3H), 7.53 (d, *J* = 5.9 Hz, 1H), 7.43 (d, *J* = 7.7 Hz, 1H), 7.35–7.27 (m, 2H), 7.07 (td, *J* = 7.6, 1.2 Hz, 1H), 5.31 (dd, *J* = 10.8, 5.6 Hz, 1H), 3.95–3.56 (m, 2H), 2.17 (s, 3H); ^{13}C NMR (126 MHz, CDCl$_3$) δ 191.50, 167.68, 165.64, 145.60, 137.74, 134.89, 134.47, 133.53, 132.42, 131.22, 130.21, 129.41, 128.65, 127.41, 125.61, 125.14, 123.97, 120.63, 55.39, 34.15, 19.21; HRMS(ESI): *m/z* [M + H]$^+$calcd for C$_{25}$H$_{22}$BrN$_2$O$_4$S$^+$: 525.0478, found: 525.0377.

(S)-N-(3-(4-Bromo-2-methoxypheny)-2-phthalimidopropionyl)-2-methylthioaniline (**3t**). **3t** was obtained as an oil. ^{1}H NMR (400 MHz, CDCl$_3$) δ 8.92 (s, 1H), 8.35 (d, *J* = 8.2 Hz, 1H), 7.85–7.79 (m, 2H), 7.78–7.70 (m, 2H), 7.45 (d, *J* = 7.7 Hz, 1H), 7.34–7.27 (m, 1H), 7.06 (td, *J* = 7.6, 1.2 Hz, 1H), 6.93 (d, *J* = 8.1 Hz, 2H), 6.85 (dd, *J* = 7.9, 1.7 Hz, 1H), 5.44 (dd, *J* = 10.8, 5.0 Hz, 1H), 3.80 (s, 3H), 3.64 (ddd, *J* = 24.6, 13.8, 7.9 Hz, 2H), 2.22 (s, 3H); ^{13}C NMR (126 MHz, CDCl$_3$) δ 167.88, 166.72, 158.38, 138.18, 134.47, 133.60, 132.17, 131.59, 129.42, 125.30, 124.78, 124.32, 123.66, 121.75, 120.55, 114.13, 55.76, 54.05, 29.94, 19.24; HRMS(ESI): *m/z* [M + H]$^+$calcd. for C$_{25}$H$_{22}$BrN$_2$O$_4$S$^+$: 525.0478, found: 525.0515.

(S)-N-(3-(5-Formyl-2-methoxyphenyl)-2-phthalimidopropionyl)-2-methylthioaniline (**3u**). **3u** was obtained as an oil. ^{1}H NMR (400 MHz, CDCl$_3$) δ 9.68 (s, 1H), 8.95 (s, 1H), 8.35 (d, *J* = 8.2 Hz, 1H), 7.82–7.77 (m, 2H), 7.74–7.68 (m, 3H), 7.58 (d, *J* = 2.0 Hz, 1H), 7.45 (d, *J* = 7.7 Hz, 1H), 7.30 (t, *J* = 7.8 Hz, 1H), 7.06 (td, *J* = 7.6, 1.1 Hz, 1H), 6.92 (d, *J* = 8.5 Hz, 1H), 5.48 (dd, *J* = 10.9, 4.8 Hz, 1H), 3.90 (s, 3H), 3.87–3.76 (m, 1H), 3.66 (dd, *J* = 13.8, 11.0 Hz, 1H), 2.21 (s, 3H); ^{13}C NMR (126 MHz, CDCl$_3$) δ 190.72, 167.80, 166.55, 162.79, 138.08, 134.55, 133.55, 132.86, 131.44, 129.70, 129.39, 129.29, 126.26, 125.36, 124.83, 123.65, 120.56, 110.60, 56.02, 53.90, 30.21, 19.21; HRMS(ESI): *m/z* [M + H]$^+$calcd. for C$_{26}$H$_{23}$N$_2$O$_5$S$^+$: 475.1322, found: 475.1361.

(S)-N-(3-(2-(Benzyloxy)-5-formylphenyl)-2-phthalimidopropionyl)-2-methylthioaniline (**3v**). **3v** was obtained as an oil. ^{1}H NMR (400 MHz, CDCl$_3$) δ 9.68 (s, 1H), 8.86 (s, 1H), 8.32 (d, *J* = 8.1 Hz, 1H), 7.76 (dt, *J* = 7.0, 3.6 Hz, 2H), 7.69 (tt, *J* = 5.6, 3.0 Hz, 3H), 7.60 (d, *J* = 2.0 Hz, 1H), 7.50 (d, *J* = 7.3 Hz, 2H), 7.46–7.36 (m, 3H), 7.31 (dd, *J* = 16.6, 7.7 Hz, 2H), 7.05 (td, *J* = 7.6, 1.3 Hz, 1H), 6.99 (d, *J* = 8.5 Hz, 1H), 5.55 (dd, *J* = 10.9, 4.8 Hz, 1H), 5.30–5.14 (m, 2H), 3.88 (dd, *J* = 13.8, 4.8 Hz, 1H), 3.71 (dd, *J* = 13.8, 11.0 Hz, 1H), 2.15 (s, 3H); ^{13}C NMR (126 MHz, CDCl$_3$) δ 190.65, 167.80, 166.40, 161.94, 138.02, 135.87, 134.49, 133.50, 133.02, 131.42, 131.26, 129.85, 129.32, 128.92, 128.42, 127.47, 126.47, 125.47, 124.82, 123.64, 120.62, 111.94, 70.85, 53.75, 30.38, 19.11;HRMS(ESI): *m/z* [M + H]$^+$calcd. for C$_{32}$H$_{27}$N$_2$O$_5$S$^+$: 551.1635, found: 551.1676.

3.3. Synthesis of the Compounds 3a and 1

Methyl (S)-3-(4-methoxy-3-formylphenyl)-2-phthalimidopropionate (**2a**). **3a** (3.0 g, 6.3 mmol), dry methanol (600 mL), conc. H_2SO_4 (5.0 mL) were added to a 500-mL round bottom flask. The mixture was stirred at 100 °C for 24 h under N_2. After cooling to room temperature, the resulting solution was evaporated, and the residue was diluted with ethyl acetate (200 mL) and brine (100 mL).The organic layer was separated and washed successively with water, saturated aqueous $NaHCO_3$ and brine, dried over anhydrous Na_2SO_4, and concentrated in vacuo. The organic layer was purified via column chromatography in a petroleum ether/ethyl acetate mixture of2:1 to produce corresponding product**2a** (1.8 g, 77%) as a solid.^{1}H NMR (500 MHz, CDCl$_3$) δ 10.31 (s, 1H), 7.84–7.75 (m, 2H), 7.74–7.65 (m, 2H), 7.60 (d, *J* = 2.4 Hz, 1H), 7.37 (dd, *J* = 8.6, 2.4 Hz, 1H), 6.83 (d, *J* = 8.6 Hz, 1H), 5.08 (dd, *J* = 11.1, 5.1 Hz, 1H), 3.84 (s, 3H), 3.77 (s, 3H), 3.60–3.42 (m, 2H); ^{13}C NMR (126 MHz, CDCl$_3$) δ 189.55, 169.24, 167.54, 160.85, 136.37, 134.35, 131.65, 129.23, 129.09, 124.79, 123.72, 112.12, 55.76, 53.32, 53.08, 33.81; HRMS(ESI): *m/z* [M + H]$^+$calcd. for $C_{20}H_{18}NO_6^+$: 368.1129, found: 368.1221.

Methyl (S)-3-(4-methoxy-3-hydroxy-phenyl)-2-phthalimidopropionate (**1**). **2a** (750 mg, 2.0 mmol), dichloromethane (50 mL), and *meta*-chloroperoxybenzoic acid(*m*-CPBA,85% purity, 770 mg, 3.8 mmol) were added to a 250-mL round bottom flask. The mixture was stirred at room temperature overnight. The resulting solution was diluted with dichloromethane(DCM, 300 mL), washed successively with saturated aqueous $Na_2S_2O_3$ and brine, dried over anhydrous Na_2SO_4, and concentrated in vacuo. The crude intermediate was used for the next step without further purification. A mixture of the concentrated residueandNaHCO$_3$ (3.4 g, 40 mmol) in tetrahydrofuran (THF,40 mL) and water (20 mL) was stirred at room temperature overnight. Then, the resulting solution was evaporated, and the residue was adjusted to pH<1 with 2 M HCl. The mixture was extracted with ethyl acetate (200 mL). The organic phase was washed with brine, dried over anhydrous Na_2SO_4, and concentrated in vacuo. This mixture was purified via column chromatography in a petroleum ether/ethyl acetate mixture of3:1 to produce corresponding product**1** (540mg, 74% yield for two steps) as a solid.^{1}H NMR (400 MHz, CDCl$_3$) δ 7.85–7.73 (m, 2H), 7.74–7.60 (m, 2H), 6.72 (d, *J* = 1.5 Hz, 1H), 6.68–6.59 (m, 2H), 5.54 (s, 1H), 5.09 (dd, *J* = 11.2, 5.2 Hz, 1H), 3.76 (s, 6H), 3.46 (qd, *J* = 14.4, 8.2 Hz, 2H); ^{13}C NMR (101 MHz, CDCl$_3$) δ 169.51, 167.61, 145.51, 134.18, 131.73, 129.96, 123.61, 120.40, 115.19, 110.78, 55.90, 53.55, 52.97, 34.11; HRMS(ESI): *m/z* [M + H]$^+$calcd. for $C_{19}H_{18}NO_6^+$: 356.1129, found: 356.1138.

3.4. Synthesis of the 4-Aryloxyphenylalanine Derivatives 6a–l

A Schlenk tube was charged with 1 (0.56 mmol), aryl iodide (2.0 equiv., or 3.0 equiv. used for synthesis of **6j**), CuI (1.0 equiv.), *N,N*-dimethylglycine hydrochloride salt (3.0 equiv.), Cs_2CO_3 (5.0 equiv.), and 5.6 mL of 1,4-dioxane, evacuated, and backfilled with N_2. The reaction mixture was stirred at 90 °C for 20 h. The suspension was filtered, and the filtrate was concentrated, followed by column chromatography on silica gel (eluting with 1:10 to 1:5 ethyl acetate/petroleum ether) to provide the desired product.

(S)-3-(3-{4-[(R)-2-Benzyloxycarbonyl-2-tert-butoxycarbonylamino]ethyl}phenoxy)-4-methoxyphenyl)-2-phthalimido-propionic acid methyl ester (**6a**). **6a** was obtained as an oil. ^{1}H NMR (400 MHz, CDCl$_3$) δ 7.77 (dt, *J* = 5.3, 2.7 Hz, 2H), 7.73–7.65 (m, 2H), 7.40–7.28 (m, 5H), 6.92 (d, *J* = 8.3 Hz, 1H), 6.81 (d, *J* = 8.3 Hz, 3H), 6.73 (s, 1H), 6.60 (d, *J* = 7.6 Hz, 2H), 5.14 (q, *J* = 12.3 Hz, 2H), 5.07–5.01 (m, 1H), 4.99 (d, *J* = 3.9 Hz, 1H), 4.64–4.51 (m, 1H), 3.75 (s, 3H), 3.72 (s, 3H), 3.53–3.35 (m, 2H), 3.01 (d, *J* = 5.7 Hz, 2H), 1.42 (s, 9H); ^{13}C NMR (126 MHz, CDCl$_3$) δ 171.88, 169.30, 167.46, 156.96, 155.27, 150.35, 144.75, 135.34, 134.30, 131.66, 130.46, 129.74, 129.68, 128.75, 128.66, 125.28, 123.68, 121.83, 121.75, 117.06, 112.97, 80.11, 67.25, 56.01, 54.63, 53.49, 53.02, 37.56, 33.94, 28.45; HRMS(ESI): *m/z* [M + Na]$^+$calcd. for $C_{40}H_{40}N_2O_{10}Na^+$: 731.2575, found: 731.2584.

(S)-3-(3-{4-[(S)-2-Benzyloxycarbonyl-2-tert-butoxycarbonylamino]ethyl}phenoxy)-4-methoxyphenyl)-2-phthalimido-propionic acid methyl ester (**6b**). **6b** was obtained as an oil. ^{1}H NMR (400 MHz, CDCl$_3$) δ 7.77 (dt, *J* = 5.3, 2.7 Hz, 2H), 7.74–7.67 (m, 2H), 7.40–7.28 (m, 5H), 6.92 (d, *J* = 8.3 Hz,

1H), 6.88–6.78 (m, 3H), 6.72 (s, 1H), 6.59 (d, *J* = 7.5 Hz, 2H), 5.23–5.07 (m, 2H), 5.07–4.94 (m, 2H), 4.65–4.49 (m, 1H), 3.75 (s, 3H), 3.72 (s, 3H), 3.55–3.33 (m, 2H), 3.00 (d, *J* = 5.7 Hz, 2H), 1.42 (s, 9H); ^{13}C NMR (126 MHz, CDCl$_3$) δ 171.86, 169.30, 167.46, 156.95, 155.27, 150.35, 144.69, 135.34, 134.30, 131.66, 130.46, 129.74, 129.69, 128.74, 128.66, 128.63, 125.27, 123.68, 121.82, 121.74, 117.02, 112.97, 80.07, 67.24, 56.01, 54.60, 53.46, 53.01, 37.54, 33.94, 28.44; HRMS(ESI): *m/z* [M + Na]$^+$calcd. for C$_{40}$H$_{40}$N$_2$O$_{10}$Na$^+$: 731.2575, found: 731.2577.

(S)-3-(3-{4-[(R)-2-(2-trimethylsilylethoxycarbonyl)-2-tert-butoxycarbonylamino]ethyl}phenoxy)-4-methoxyphenyl)-2-phthalimido-propionic Acid Methyl Ester (**6c**). **6c** was obtained as an oil. ^{1}H NMR (400 MHz, CDCl$_3$) δ 7.78 (dt, *J* = 7.6, 2.9 Hz, 2H), 7.75–7.69 (m, 2H), 6.91 (dd, *J* = 8.3, 1.8 Hz, 3H), 6.80 (d, *J* = 8.4 Hz, 1H), 6.73 (s, 1H), 6.65 (d, *J* = 7.1 Hz, 2H), 5.04 (dd, *J* = 11.4, 5.1 Hz, 1H), 4.97 (d, *J* = 7.9 Hz, 1H), 4.49 (d, *J* = 5.4 Hz, 1H), 4.27–4.10 (m, 2H), 3.75 (s, 3H), 3.72 (d, *J* = 1.4 Hz, 3H), 3.45 (ddd, *J* = 25.8, 14.4, 8.3 Hz, 2H), 3.11–2.87 (m, 2H), 1.42 (s, 9H), 0.98 (dd, *J* = 9.7, 7.6 Hz, 2H), 0.04 (d, *J* = 0.7 Hz, 9H); ^{13}C NMR (126 MHz, CDCl$_3$) δ 172.15, 169.30, 167.46, 156.91, 155.28, 150.34, 144.78, 134.31, 131.69, 130.49, 130.08, 129.70, 125.23, 123.69, 121.76, 121.69, 117.04, 112.99, 79.97, 63.88, 56.03, 54.67, 53.49, 53.01, 37.64, 33.95, 28.46, 17.49, −1.38; HRMS(ESI): *m/z* [M + Na]$^+$ calcd. for C$_{38}$H$_{46}$N$_2$O$_{10}$SiNa$^+$: 741.2814, found: 741.2805.

(S)-3-(3-{4-[(R)-2-Allyloxycarbonyl-2-tert-butoxycarbonylamino]ethyl}phenoxy)-4-methoxyphenyl)-2-phthalimido-propionic acid methyl ester (**6d**). **6d** was obtained as an oil. ^{1}H NMR (400 MHz, CDCl$_3$) δ 7.78 (dt, *J* = 7.5, 2.9 Hz, 2H), 7.75–7.70 (m, 2H), 6.91 (d, *J* = 8.3 Hz, 3H), 6.80 (d, *J* = 8.4 Hz, 1H), 6.73 (d, *J* = 1.3 Hz, 1H), 6.65 (dd, *J* = 8.6, 2.4 Hz, 2H), 5.87 (ddt, *J* = 16.9, 11.3, 5.8 Hz, 1H), 5.28 (dd, *J* = 22.7, 13.8 Hz, 2H), 5.04 (dd, *J* = 11.4, 5.1 Hz, 1H), 4.99 (d, *J* = 5.0 Hz, 1H), 4.60 (d, *J* = 5.8 Hz, 2H), 4.56 (s, 1H), 3.75 (s, 3H), 3.72 (s, 3H), 3.45 (dd, *J* = 16.9, 8.3 Hz, 2H), 3.02 (d, *J* = 5.3 Hz, 2H), 1.42 (s, 9H); ^{13}C NMR (126 MHz, CDCl$_3$) δ 171.75, 169.30, 167.46, 156.96, 155.27, 150.34, 144.76, 134.31, 131.68, 130.48, 129.89, 129.70, 125.26, 123.69, 121.76, 121.69, 119.05, 117.09, 112.99, 80.08, 66.06, 56.03, 54.64, 53.47, 53.02, 37.65, 33.95, 28.45; HRMS(ESI): *m/z* [M + Na]$^+$calcd. for C$_{36}$H$_{38}$N$_2$O$_{10}$Na$^+$: 681.2419, found: 681.2408.

(S)-Methyl 2-phthalimido-3-(3-(4-formylphenoxy)-4-methoxyphenyl)-propanoate (**6e**). **6e** was obtained as an oil. ^{1}H NMR (400 MHz, CDCl$_3$) δ 9.86 (s, 1H), 7.77 (dt, *J* = 6.9, 3.6 Hz, 2H), 7.74–7.68 (m, 2H), 7.68–7.62 (m, 2H), 7.04 (dd, *J* = 8.4, 2.1 Hz, 1H), 6.86 (dd, *J* = 5.3, 3.1 Hz, 2H), 6.76 (d, *J* = 8.7 Hz, 2H), 5.07 (dd, *J* = 11.4, 5.2 Hz, 1H), 3.77 (s, 3H), 3.69 (s, 3H), 3.50 (qd, *J* = 14.4, 8.3 Hz, 2H); ^{13}C NMR (126 MHz, CDCl$_3$) δ 190.90, 169.20, 167.51, 163.51, 150.60, 142.83, 134.41, 131.90, 131.59, 130.88, 130.05, 126.84, 123.69, 123.19, 116.20, 113.24, 55.98, 53.47, 53.09, 33.89; HRMS(ESI): *m/z* [M + H]$^+$calcd. for C$_{26}$H$_{22}$NO$_7$$^+$: 460.1391, found: 460.1394.

(S)-Methyl 2-phthalimido-3-(3-(3-formylphenoxy)-4-methoxyphenyl)-propanoate (**6f**). **6f** was obtained as an oil. ^{1}H NMR (400 MHz, CDCl$_3$) δ 9.89 (s, 1H), 7.82–7.74 (m, 2H), 7.73–7.67 (m, 2H), 7.51 (d, *J* = 7.6 Hz, 1H), 7.34 (t, *J* = 7.8 Hz, 1H), 7.20 (dd, *J* = 2.3, 1.4 Hz, 1H), 7.08–7.02 (m, 1H), 7.00–6.94 (m, 1H), 6.83 (d, *J* = 8.6 Hz, 2H), 5.06 (dd, *J* = 11.3, 5.2 Hz, 1H), 3.76 (s, 3H), 3.71 (s, 3H), 3.56–3.40 (m, 2H); ^{13}C NMR (126 MHz, CDCl$_3$) δ 192.02, 169.25, 167.51, 158.89, 150.52, 143.76, 137.94, 134.34, 131.61, 130.21, 129.96, 126.24, 123.68, 122.87, 122.45, 117.03, 113.14, 55.99, 53.41, 53.06, 33.94; HRMS(ESI): *m/z* [M + H]$^+$calcd. for C$_{26}$H$_{22}$NO$_7$$^+$: 460.1391, found: 460.1394.

(S)-Methyl2-phthalimido-3-(3-(3-formyl-4-methoxyphenoxy)-4-methoxyphenyl)-propanoate(**6g**). **6g** was obtained as an oil. ^{1}H NMR (400 MHz, CDCl$_3$) δ 10.38 (s, 1H), 7.83–7.74 (m, 2H), 7.74–7.67 (m, 2H), 7.23 (d, *J* = 3.1 Hz, 1H), 7.08 (dd, *J* = 9.0, 3.2 Hz, 1H), 6.91–6.85 (m, 2H), 6.79 (d, *J* = 8.4 Hz, 1H), 6.67 (d, *J* = 2.1 Hz, 1H), 5.04 (dd, *J* = 11.3, 5.3 Hz, 1H), 3.92 (s, 3H), 3.75 (s, 3H), 3.74 (s, 3H), 3.44 (qd, *J* = 14.4, 8.3 Hz, 2H); ^{13}C NMR (126 MHz, CDCl$_3$) δ 189.25, 169.32, 167.49, 157.75, 151.28, 149.93, 145.40, 134.27, 131.62, 129.69, 125.59, 125.41, 125.07, 123.67, 120.62, 116.84, 113.04, 112.90, 56.20, 56.00, 53.30, 53.00, 33.93; HRMS(ESI): *m/z* [M + H]$^+$calcd. for C$_{27}$H$_{24}$NO$_8$$^+$: 490.1496, found: 490.1510.

(S)-Methyl 2-phthalimido-3-(4-methoxy-3-(4-nitrophenoxy)phenyl)-propanoate (**6h**). **6h** was obtained as an oil. ^{1}H NMR (400 MHz, CDCl$_3$) δ 8.04–7.95 (m, 2H), 7.80–7.75 (m, 2H), 7.75–7.70 (m, 2H), 7.07 (dd, *J* = 8.4, 2.1 Hz, 1H), 6.87 (d, *J* = 8.7 Hz, 2H), 6.73–6.65 (m, 2H), 5.07 (dd,

J = 11.4, 5.2 Hz, 1H), 3.77 (s, 3H), 3.69 (s, 3H), 3.51 (qd, *J* = 14.4, 8.3 Hz, 2H); ^{13}C NMR (126 MHz, CDCl$_3$) δ 169.13, 167.49, 163.59, 150.51, 142.43, 142.26, 134.47, 131.54, 130.17, 127.29, 125.83, 123.70, 123.28, 115.76, 113.30, 55.94, 53.45, 53.12, 33.87; HRMS(ESI): *m/z* [M + H]$^+$calcd. for C$_{25}$H$_{21}$N$_2$O$_8$$^+$: 477.1292, found: 477.1304.

(S)-Methyl 2-phthalimido-3-(3-(4-cyanophenoxy)-4-methoxyphenyl)-propanoate (**6i**). **6i** was obtained as an oil. ^{1}H NMR (400 MHz, CDCl$_3$) δ 7.81–7.69 (m, 4H), 7.44–7.35 (m, 2H), 7.03 (dd, *J* = 8.4, 2.1 Hz, 1H), 6.85 (t, *J* = 4.9 Hz, 2H), 6.75–6.64 (m, 2H), 5.06 (dd, *J* = 11.4, 5.2 Hz, 1H), 3.77 (s, 3H), 3.69 (s, 3H), 3.49 (qd, *J* = 14.4, 8.3 Hz, 2H); ^{13}C NMR (126 MHz, CDCl$_3$) δ 169.14, 167.48, 161.89, 150.56, 142.51, 134.42, 133.97, 131.58, 130.12, 127.04, 123.68, 123.19, 119.12, 116.56, 113.25, 105.20, 55.95, 53.46, 53.10, 33.86; HRMS(ESI): *m/z* [M + H]$^+$calcd. for C$_{26}$H$_{21}$N$_2$O$_6$$^+$: 457.1394, found: 457.1401.

(S)-Methyl 2-phthalimido-3-(3-(4-iodophenoxy)-4-methoxyphenyl)-propanoate (**6j**). **6j** was obtained as an oil. ^{1}H NMR (400 MHz, CDCl$_3$) δ 7.83–7.68 (m, 4H), 7.40–7.32 (m, 2H), 6.96 (dd, *J* = 8.4, 2.1 Hz, 1H), 6.85–6.78 (m, 1H), 6.73 (d, *J* = 2.1 Hz, 1H), 6.49–6.41 (m, 2H), 5.04 (dd, *J* = 11.4, 5.2 Hz, 1H), 3.76 (s, 3H), 3.72 (s, 3H), 3.55–3.36 (m, 2H); ^{13}C NMR (126 MHz, CDCl$_3$) δ 169.23, 167.48, 158.04, 150.39, 144.11, 138.34, 134.37, 131.60, 129.87, 125.86, 123.68, 122.07, 119.04, 113.10, 84.92, 56.02, 53.55, 53.06, 33.89; HRMS(ESI): *m/z* [M + H]$^+$calcd. for C$_{25}$H$_{21}$INO$_6$$^+$: 558.0408, found: 558.0411.

(S)-Methyl 2-phthalimido-3-(3-(4-acetylphenoxy)-4-methoxyphenyl)-propanoate (**6k**). **6k** was obtained as an oil. ^{1}H NMR (400 MHz, CDCl$_3$) δ 7.81–7.75 (m, 3H), 7.71 (tt, *J* = 8.8, 2.5 Hz, 3H), 7.01 (dd, *J* = 8.4, 2.1 Hz, 1H), 6.85 (d, *J* = 8.1 Hz, 2H), 6.73–6.67 (m, 2H), 5.10–5.03 (m, 1H), 3.77 (s, 3H), 3.70 (s, 3H), 3.57–3.39 (m, 2H), 2.54 (s, 3H); ^{13}C NMR (126 MHz, CDCl$_3$) δ 196.85, 169.22, 167.50, 162.31, 150.58, 143.11, 134.39, 131.57, 131.38, 130.54, 129.95, 126.55, 123.69, 123.00, 115.75, 113.18, 55.98, 53.47, 53.08, 33.90, 26.58; HRMS(ESI): *m/z* [M + H]$^+$calcd. for C$_{27}$H$_{24}$NO$_7$$^+$: 474.1547, found: 474.1573.

(S)-Methyl 2-phthalimido-3-(3-(4-methoxycarbonyl-3-benzyloxyphenoxy)-4-methoxyphenyl)-propanoate (**6l**). **6l** was obtained as an oil. ^{1}H NMR (400 MHz, CDCl$_3$) δ 7.75 (dd, *J* = 5.5, 3.0 Hz, 2H), 7.67 (dd, *J* = 5.4, 3.1 Hz, 2H), 7.62 (d, *J* = 8.7 Hz, 1H), 7.45 (d, *J* = 7.3 Hz, 2H), 7.36 (t, *J* = 7.4 Hz, 2H), 7.30 (d, *J* = 7.3 Hz, 1H), 6.99 (dd, *J* = 8.4, 2.1 Hz, 1H), 6.82 (dd, *J* = 8.3, 5.3 Hz, 2H), 6.49 (d, *J* = 2.3 Hz, 1H), 6.15 (dd, *J* = 8.7, 2.3 Hz, 1H), 5.08 (s, 2H), 5.07–5.01 (m, 1H), 3.88 (s, 3H), 3.77 (s, 3H), 3.64 (s, 3H), 3.55–3.39 (m, 2H); ^{13}C NMR (126 MHz, CDCl$_3$) δ 169.21, 167.51, 166.29, 162.81, 160.25, 150.56, 143.14, 136.75, 134.38, 133.72, 131.56, 129.97, 128.64, 127.84, 126.95, 126.49, 123.67, 122.94, 113.97, 113.07, 107.60, 102.16, 70.47, 55.91, 53.54, 53.07, 51.89, 33.93; HRMS(ESI): *m/z* [M + H]$^+$calcd. for C$_{34}$H$_{30}$NO$_9$$^+$: 596.1915, found: 596.1930.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/md21070373/s1, Copies of NMR spectra.

Author Contributions: Z.-C.S. and C.-G.H. designed the study. Y.X. performed the experiments, analyzed and interpreted the data, and drafted the manuscript. P.H., Z.X., X.-T.T., Y.-H.L. and H.-D.J. contributed to discussions. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Data Availability Statement: The original data presented in the study are included in the article/Supplementary Materials; further inquiries can be directed to the corresponding author.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Kim, G.J.; Li, X.; Kim, S.; Yang, I.; Hahn, D.; Chin, J.; Nam, S.; Nam, J.; Nam, D.H.; Oh, D.; et al. Seongsanamides A–D: Antiallergic Bicyclic Peptides from *Bacillus safensis* KCTC 12796BP. *Org. Lett.* **2018**, *20*, 7539–7543. [CrossRef]
2. Skaff, O.; Jolliffe, K.A.; Hutton, C.A. Synthesis of the Side Chain Cross-Linked Tyrosine Oligomers Dityrosine, Trityrosine, and Pulcherosine. *J. Org. Chem.* **2005**, *70*, 7353–7363. [CrossRef]

3. Jung, M.E.; Lazarova, T. New Efficient Method for the Total Synthesis of (*S*,*S*)-Isodityrosine from Natural Amino Acids. *J. Org. Chem.* **1999**, *64*, 2976–2977. [CrossRef]

4. Fan, J.-T.; Su, J.; Peng, Y.-M.; Li, Y.; Li, J.; Zhou, Y.-B.; Zeng, G.-Z.; Yan, H.; Tan, N.-H. Rubiyunnanins C–H, Cytotoxic Cyclic Hexapeptides from *Rubia yunnanensis* Inhibiting Nitric Oxide Production and NF-κB Activation. *Bioorgan. Med. Chem.* **2010**, *18*, 8226–8234. [CrossRef]

5. Hitotsuyanagi, Y.; Sasaki, S.; Matsumoto, Y.; Yamaguchi, K.; Itokawa, H.; Takeya, K. Synthesis of [L-Ala-1]RA-VII, [D-Ala-2]RA-VII, and [D-Ala-4]RA-VII by Epimerization of RA-VII, an Antitumor Bicyclic Hexapeptide from Rubia Plants, through Oxazoles. *J. Am. Chem. Soc.* **2003**, *125*, 7284–7290. [CrossRef] [PubMed]

6. Chen, T.; Xiong, H.; Yang, J.F.; Zhu, X.L.; Qu, R.Y.; Yang, G.F. Diaryl Ether: A Privileged Scaffold for Drug and Agrochemical Discovery. *J. Agric. Food Chem.* **2020**, *68*, 9839–9877. [CrossRef] [PubMed]

7. Robello, M.; Barresi, E.; Baglini, E.; Salerno, S.; Taliani, S.; Settimo, F.D. The Alpha Keto Amide Moiety as a Privileged Motif in Medicinal Chemistry: Current Insights and Emerging Opportunities. *J. Med. Chem.* **2021**, *64*, 3508–3545. [CrossRef] [PubMed]

8. Talele, T.T. Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry. *J. Med. Chem.* **2018**, *61*, 2166–2210. [CrossRef]

9. Gupta, A.; Sen, S.; Harmata, M.; Pulley, S.R. Synthesis of (*S*,*S*)-Isodityrosine by Dötz Benzannulation. *J. Org. Chem.* **2005**, *70*, 7422–7425. [CrossRef]

10. Nolasco, L.; Gonzalez, M.P.; Caggiano, L.; Jackson, R.F.W. Application of Negishi Cross-Coupling to the Synthesis of the Cyclic Tripeptides OF4949-III and K-13. *J. Org. Chem.* **2009**, *74*, 8280–8289. [CrossRef]

11. Boger, D.L.; Yohannes, D.; Zhou, J.; Patane, M.A. Total Synthesis of Cycloisodityrosine, RA-VII, Deoxybouvardin, and N^{29}-Desmethyl-RA-VII: Identification of the Pharmacophore and Reversal of the Subunit Functional Roles. *J. Am. Chem. Soc.* **1993**, *115*, 3420–3430. [CrossRef]

12. Boger, D.L.; Yohannes, D. Total Synthesis of K-13. *J. Org. Chem.* **1989**, *54*, 2498–2502. [CrossRef]

13. Boger, D.L.; Zhou, J. *N*-Desmethyl Derivatives of Deoxybouvardin and RA-VII: Synthesis and Evaluation. *J. Am. Chem. Soc.* **1995**, *117*, 7364–7378. [CrossRef]

14. Boger, D.L.; Sakya, S.M.; Yohannes, D. Total Synthesis of Combretastatin D-2: Intramolecular Ullmann Macrocyclization Reaction. *J. Org. Chem.* **1991**, *56*, 4204–4207. [CrossRef]

15. Boger, D.L.; Yohannes, D. Total Synthesis of L, L-Isodityrosine and Isodityrosine-Derived Agents: K-13, OF4949-III, and OF4949-IV. *J. Org. Chem.* **1990**, *55*, 6000–6017. [CrossRef]

16. Cai, Q.; He, G.; Ma, D. Mild and Nonracemizing Conditions for Ullmann-type Diaryl Ether Formation between Aryl Iodides and Tyrosine Derivatives. *J. Org. Chem.* **2006**, *71*, 5268–5273. [CrossRef] [PubMed]

17. Shabani, S.; Hutton, C.A. Total Synthesis of Seongsanamide B. *Org. Lett.* **2020**, *22*, 4557–4561. [CrossRef]

18. Han, F.; Guo, Y.; Ye, T. Total Synthesis of Antiallergic Bicyclic Peptide Seongsanamide A. *Org. Chem. Front.* **2020**, *7*, 1658–1662. [CrossRef]

19. Mondal, S.; Chowdhury, S. Recent Advances on Amino Acid Modifications via C–H Functionalization and Decarboxylative Functionalization Strategies. *Adv. Synth. Catal.* **2018**, *360*, 1884–1912. [CrossRef]

20. Noisier, A.F.M.; Brimble, M.A. C–H Functionalization in the Synthesis of Amino Acids and Peptides. *Chem. Rev.* **2014**, *114*, 8775–8806. [CrossRef]

21. He, J.; Wasa, M.; Chan, K.S.L.; Shao, Q.; Yu, J.-Q. Palladium-Catalyzed Transformations of Alkyl C–H Bonds. *Chem. Rev.* **2017**, *117*, 8754–8786. [CrossRef]

22. Rej, S.; Ano, Y.; Chatani, N. Bidentate Directing Groups: An Efficient Tool in C–H Bond Functionalization Chemistry for the Expedient Construction of C–C Bonds. *Chem. Rev.* **2020**, *120*, 1788–1887. [CrossRef] [PubMed]

23. Rouquet, G.; Chatani, N. Catalytic Functionalization of C(sp^2)–H and C(sp^3)–H Bonds by Using Bidentate Directing Groups. *Angew. Chem. Int. Ed.* **2013**, *52*, 11726–11743. [CrossRef] [PubMed]

24. Chen, K.; Zhang, S.-Q.; Xu, J.-W.; Hu, F.; Shi, B.-F. A General and Practical Palladium-catalyzed Monoarylation of β-methyl C(sp^3)–H of Alanine. *Chem. Commun.* **2014**, *50*, 13924–13927. [CrossRef] [PubMed]

25. Wang, B.; Nack, W.A.; He, G.; Zhang, S.-Y.; Chen, G. Palladium-catalyzed Trifluoroacetate-promoted mono-Arylation of the β-methyl group of Alanine at room temperature: Synthesis of β-Arylated α-Amino Acids through Sequential C–H Functionalization. *Chem. Sci.* **2014**, *5*, 3952–3957. [CrossRef]

26. Affron, D.P.; Davis, O.A.; Bull, J.A. Regio- and Stereospecific Synthesis of C-3 Functionalized Proline Derivatives by Palladium Catalyzed Directed C(sp^3)–H Arylation. *Org. Lett.* **2014**, *16*, 4956–4959. [CrossRef] [PubMed]

27. Tran, L.D.; Daugulis, O. Nonnatural Amino Acid Synthesis by Using Carbon–Hydrogen Bond Functionalization Methodology. *Angew. Chem. Int. Ed.* **2012**, *51*, 5188–5191. [CrossRef]

28. Xiao, K.; Lin, D.W.; Miura, M.; Zhu, R.; Gong, W.; Wasa, M.; Yu, J.-Q. Palladium(II)-Catalyzed Enantioselective C(sp^3)–H Activation Using a Chiral Hydroxamic Acid Ligand. *J. Am. Chem. Soc.* **2014**, *136*, 8138–8142. [CrossRef]

29. Zhang, Q.; Chen, K.; Rao, W.; Zhang, Y.; Chen, F.-J.; Shi, B.-F. Stereoselective Synthesis of Chiral α-Amino-β-Lactams through Palladium(II)-Catalyzed Sequential Monoarylation/Amidation of C(sp^3)–H Bonds. *Angew. Chem. Int. Ed.* **2013**, *52*, 13588–13592. [CrossRef]

30. Monnier, F.; Taillefer, M. Catalytic C–C, C–N, and C–O Ullmann-Type Coupling Reactions. *Angew. Chem. Int. Ed.* **2009**, *48*, 6954–6971. [CrossRef]

31. Ma, D.; Cai, Q. *N*, *N*-Dimethyl Glycine-Promoted Ullmann Coupling Reaction of Phenols and Aryl Halides. *Org. Lett.* **2003**, *5*, 3799–3802. [CrossRef] [PubMed]

32. Ma, D.; Cai, Q.; Zhang, H. Mild Method for Ullmann Coupling Reaction of Amines and Aryl Halides. *Org. Lett.* **2003**, *5*, 2453–2455. [CrossRef] [PubMed]

33. Zhai, Y.; Chen, X.; Zhou, W.; Fan, M.; Lai, Y.; Ma, D. Copper-Catalyzed Diaryl Ether Formation from (Hetero)aryl Halides at Low Catalytic Loadings. *J. Org. Chem.* **2017**, *82*, 4964–4969. [CrossRef]

34. Fan, M.; Zhou, W.; Jiang, Y.; Ma, D. CuI/Oxalamide Catalyzed Couplings of (Hetero)aryl Chlorides and Phenols for Diaryl Ether Formation. *Angew. Chem. Int. Ed.* **2016**, *55*, 6211–6215. [CrossRef] [PubMed]